Suppressor T Cells in BCG-Treated Mice and Their Impact on Tumor Immunity
Author Information
Author(s): B. Payellel, M. Brulay-Rosset, M.F. Poupon, G. Lespinats
Primary Institution: Laboratoire d'Immunobiologie - Institut de Recherches Scientifiques sur le Cancer
Hypothesis
Does BCG treatment interfere with the induction and expression of a specific antitumoral immune response?
Conclusion
High doses of BCG can completely prevent the generation of specific protective T cells and abrogate established antitumor immunity.
Supporting Evidence
- BCG treatment at high doses eliminated established antitumor immunity.
- Suppressor T cells were identified as responsible for the inhibition of the immune response.
- Low doses of BCG did not modify the protective effect induced by hybrid tumor cells.
Takeaway
When mice are treated with a vaccine called BCG, it can stop their immune system from fighting tumors, especially if given in high doses.
Methodology
The study used B6 mice and involved immunization against a fibrosarcoma, followed by BCG treatment and various assays to evaluate immune response.
Potential Biases
Potential bias due to the use of a single mouse strain and specific tumor model.
Limitations
The study primarily focused on a specific mouse model, which may not fully represent human responses.
Participant Demographics
Female C57BL/6 (B6) mice, aged 8 to 12 weeks.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website